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IL-4 has been implicated to play an important role in
the pathogenesis of many in¯ammatory diseases
including skin diseases such as atopic dermatitis.
Because it is not clear which pathologic features of
atopic dermatitis are dependent on IL-4, we assessed
the consequences of IL-4 overexpression in the skin,
using transgenic mice overexpressing IL-4 ubiqui-
tously. Although transgenic mice display no clinical
signs of skin in¯ammation, IL-4 induced a wide
spectrum of pathologies including an increased num-
ber of mast cells and Langerhans cells in dermis and
epidermis, respectively, focal deposition of collagen
and a considerably reduced adipocyte layer in the
dermis as well as an increased mitotic activity of ker-
atinocytes, re¯ected in acanthosis and hyperkeratosis.
The increase in Langerhans cell number may be
explained in part by the substantially reduced
Langerhans cell emigration from the epidermis in
transgenic mice. The molecular mechanism behind
this phenomenon remains to be clari®ed. Under
in vitro culture conditions, Langerhans cells from
transgenic mice undergo a maturation process simi-
lar to that of Langerhans cells from control mice,
and their immunostimulatory capacity is also com-
parable. In contrast, transgenic Langerhans cells are
superior to control Langerhans cells in their antigen-
processing capacity. We conclude that the overex-
pression of IL-4 in the skin is, by itself, not suf®cient
for the induction of a full-blown atopic dermatitis
phenotype, but several changes seen in the skin of
transgenic mice mirror the cardinal pathologic mani-
festations of this disease. Keywords: adipocyte/IL-4
transgenic/keratinocyte/Langerhans cell/mast cell. J Invest
Dermatol 118:767±778, 2002
T
he prevalence of chronic in¯ammatory skin diseases of
atopic nature, such as chronic atopic dermatitis (AD),
is still rising. In many cases, it is associated with
elevated serum IgE levels, peripheral blood eosino-
philia, as well as rhinoconjunctivitis and/or bronchial
asthma. Genetic susceptibility, abnormal lipid synthesis with
epidermal barrier dysfunction, and an altered in¯ammatory and
immune response to irritants and allergens were suggested to
contribute to AD pathogenesis (Leung, 1995; Rudikoff and
Lebwohl, 1998). Acute or early lesions of AD are characterized
by spongiosis and a sparse epidermal in®ltrate of T lymphocytes.
There is often marked dermal edema with a prominent in®ltrate of
in¯ammatory cells, particularly T lymphocytes. Mast cells are only
slightly increased in number, but they are in various stages of
degranulation, which indicates activation of these cells. Chronic
lesions of AD exhibit hyperkeratosis, epidermal hyperplasia,
minimal spongiosis, and upper dermal ®brosis. The dermal
in¯ammatory in®ltrate is composed mainly of macrophages and
eosinophils, which have been found to release major basic protein
(Rudikoff and Lebwohl, 1998). An increased number of
not-activated mast cells, and cells belonging to the dendritic cell
(DC) lineage, including dermal DC, epidermal Langerhans cells,
and a distinct population of in¯ammatory dendritic epidermal cells
expressing CD1a, CD1b, or CD36, or combinations thereof, has
also been observed (Bos et al, 1986; Bieber et al, 1988; Taylor et al,
1991; Horsmanheimo et al, 1994; Rudikoff and Lebwohl, 1998).
Additional characteristics of DC in AD are the markedly
upregulated expression of the high-af®nity receptor for IgE
(FceRI) (Wollenberg et al, 1996; Klubal et al, 1997) and CD86
(Ohki et al, 1997). In¯ux of activated T lymphocytes into the skin
lesions represents a hallmark in AD (Grewe et al, 1998) and recent
results indicate a dynamic T cell-derived cytokine production in
AD. In addition to the well-known Th2/Tc2 component of acute
lesions (Akdis et al, 1999), chronic lesions are characterized by an
Th1/Th0 cytokine pattern (Grewe et al, 1998). To what degree IL-
4 contributes to the development and perpetuation of underlying
pathologies remains speculative. IL-4 is a pleiotropic cytokine and
is produced by CD4+ helper T cells of the Th2 subset, some CD8+
T cells, activated mast cells, basophils, and eosinophils. IL-4 affects a
broad spectrum of different cell types including T cells, B cells,
natural killer cells, mast cells, monocytes/macrophages, endothelial
cells, ®broblasts, adipocytes, DC, Langerhans cells, and keratino-
cytes and regulates the immune response in a number of ways
(Chomarat et al, 1998). In T cells, IL-4 directs the development of
undifferentiated T cells into IL-4-producing Th2 cells (Brown and
Hural, 1997; Chomarat et al, 1998). IL-4 promotes growth and
increased survival in B cells, enhances their antigen-presenting
capacity by increasing the expression of MHC class II molecules
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and low-af®nity Fce receptors, and Th2-derived IL-4 induces
isotype switching from IgM to IgG1 and IgE production in B cells.
As it has long been recognized that IL-4 plays a crucial role in
directing the adaptive immune response of T and B cells and that
IL-4 is a key factor in the pathogenesis of atopy, therapeutic
strategies aiming to block IL-4 activity (e.g., by monoclonal
antibodies, soluble receptors, or small molecular compounds) have
been developed mostly to prevent asthma and other IgE-mediated
diseases (Renz, 1999; Wong and Koh, 2000; Mitchell and Abbas,
2001; Stutz et al, 2001; Tomkinson et al, 2001). Conceivably, such
an approach could also be useful in the treatment of AD, because
IL-4 also in¯uences cells known to be phenotypically and/or
functionally altered in AD, i.e., keratinocytes, ®broblasts, endothe-
lial cells, and Langerhans cells.
While this report was in progress, a study was published where
transgenic (tg) mice were generated expressing epidermal IL-4
(Chan et al, 2001). Interestingly, the normal appearing skin of these
mice revealed no pathology; however, a large percentage of these
mice spontaneously developed a pruritic in¯ammatory skin disease
with many of the key features of AD.
We studied the structural, phenotypic, and functional properties
of skin and individual skin cell populations in tg mice over-
expressing IL-4 ubiquitously (Erb et al, 1994), and found that IL-4
failed to induce a spontaneous skin disease but induced a wide
spectrum of pathologies including an increased number of
Langerhans cells, mast cells, focal deposition of collagen, a reduced
adipocyte layer, acanthosis, and hyperkeratosis.
MATERIALS AND METHODS
Mice Newborn to 42-wk-old female IL-4 tg mice [B6C3HF1
(H-2b/k)] were used in the experiments (Erb et al, 1994). The non-tg
offspring served as age-matched, littermate controls. Six to twelve-wk-
old female inbred mice [BALB/c (H-2d)] were obtained from Charles
River Wiga GmbH (Sulzfeld, Germany).
Reagents RPMI 1640 medium was supplemented with 10% heat-
inactivated fetal calf serum (PAA Laboratories GmbH, Linz, Austria),
25 mM HEPES, 10 mg gentamycin per ml, 2 mM L-glutamine, 0.1 mM
nonessential amino acids, 1 mM sodium pyruvate, 50 mM 2-ME, and
1 3 antibiotic-antimycotic solution (all from Gibco Life Technologies,
Grand Island, NY). Unlabeled or FITC-conjugated monoclonal
antibodies (MoAb) 145±2C11 and 500A2 (anti-CD3), GK1.5 and RM4-
4 (anti-CD4), 53±6.72 (anti-CD8), B3B4 (anti-CD23), J11d and M1/69
(anti-CD24), 3C7 and 7D4 (anti-CD25), Ha2/5 (anti-CD29), 3/23
(anti-CD40), IM7.8.1 (anti-CD44), 30F11.1 (anti-CD45), 23G2 (anti-
CD45RB), R1-2 (CD49d), RA3±6B2 (anti-CD45R/B220), 3E2 (anti-
CD54), MEL-14 (anti-CD62L), 16±10A1 (anti-CD80), GL1 (anti-
CD86), and G7 (anti-CD90) were purchased from PharMingen (San
Diego, CA). The MoAb NLDC-145 (anti-DEC-205), ECCD-2 (anti-E-
cadherin), F7D5 (anti-CD90), and the polyclonal antibody Ki-67 were
obtained from Serotec (Oxford, U.K.), Zymed (South San Francisco,
CA), Biosource (Camarillo, CA), and Novocastra (Newcastle, U.K.),
respectively. Hybridomas N418 (anti-CD11c, HB 224), M5/114.15.2
(anti-I-Ab,d,q & I-Ed,k, TIB 120), RA3±3A1/6.1 (anti-CD45R/B220,
TIB 146), and F4/80 (antimacrophage, HB 198) were obtained from the
American Type Culture Collection (Manassas, VA). The hybridomas
2B6.2D8 (anti-CD4) and 3.168.81 (anti-CD8) were kindly provided by
E. M. Shevach (National Institute of Allergy and Infectious Diseases,
Bethesda, MD), and H. R. MacDonald (Ludwig Institute for Cancer
Research, Epalinges, Switzerland), respectively. Second step reagents
were polyclonal FITC-labeled F(ab¢)2 goat antirat IgG (H + L)
(Immunotech, Marseille, France), FITC-conjugated goat antihamster IgG
(H + L) (Caltag, South San Francisco, CA), Streptavidin-Phycoerythrin
(SAv-PE) (PharMingen) or Streptavidin Texas Red (Amersham
Pharmacia Biotech, Vienna, Austria). Irrelevant, isotype-matched MoAb
were used as negative controls. Some of the MoAb used were puri®ed
from supernatants of the corresponding hybridomas, and protein
concentrations were adjusted to 1 mg per ml before they were FITC-
conjugated or biotinylated. Hen egg lysozyme (HEL) and ovalbumin
(OVA) were purchased from Sigma (St. Louis, MO).
Epidermal cells (EC) Ears from tg mice and controls were washed
in 70% ethanol, dried, split, placed dermal side down on a dispase II/
PBS solution (2.4 U per ml; Boehringer Mannheim, Mannheim,
Germany) for 45 min at 37°C. In some experiments trunk skin was used.
Epidermal sheets were peeled from the dermis and further digested by
stirring in a trypsin-GNK solution (0.1% trypsin, sodium bicarbonate,
NaCl, KCl, and glucose) containing DNase (200 mg per ml) for 20 min
at 37°C. The single cell suspension was ®ltered through a cell strainer
and total cell number [number of isolated cells per ear: control: 7 3 105;
tg: 8 3 105 (n = 8)] and viability (> 95%) were assessed. EC either were
used for ¯ow cytometry analyzes and antigen-processing assays or were
cultured (1.5 3 106 cells per ml) in 75 cm2 ¯asks (Costar, Cambridge,
MA) at 37°C. After 3 d, nonadherent EC were harvested and dead cells
were largely eliminated by density gradient centrifugation (Lympholyte-
M, Cedarlane Laboratories, Hornby, Ontario, Canada). The resulting cell
suspension was either analyzed by ¯ow cytometry or prepared for FACS-
sorting experiments. Brie¯y, cultured EC were incubated with a FITC-
labeled anti-DEC-205 MoAb and subsequently sorted with a FACS
Vantage (Becton Dickinson, Mountain View, CA), yielding a highly
viable (> 98%) suspension of >95% DEC-205+ cells. Keratinocytes from
control and tg mice were isolated and cultured (1 3 106 cells per well)
in 24-well plates as described (Carroll et al, 1995). At selected time
points, adherent and nonadherent keratinocytes were harvested from
both cultures, and cell numbers and viability were assessed.
IL-4 ELISA EC suspensions of control and tg mice were cultured
(2 3 106 cells per ml) in 24-well plates (Costar). At selected time points,
supernatants were collected and stored at ±20°C until use. IL-4
concentrations were determined by ELISA (Endogen, Woburn, MA)
according to the manufacturer's instructions.
Histology, immunocytochemistry, and ultrastructural analyzes Ear
thickness of anesthesized control and tg mice (7±15 mice per group) was
measured using an engineer's micrometer (Hahn und Kolb, Stuttgart,
Germany). Alternatively, adult mice were killed and the ears and skin of
the midback region were removed and cut in half. One half was
embedded and snap frozen in liquid nitrogen, the other half was ®xed in
4% neutral-buffered formalin, routinely processed and embedded either
in paraf®n or in Technovit 7100 (Kulzer, Wehrheim, Germany).
Sections (3 mm) were stained using (i) Masson trichrome, for the
identi®cation of collagen ®bers; (ii) 10% Giemsa solution (Merck,
Darmstadt, Germany) at pH 5.5, for the identi®cation of eosinophils and
mast cells; (iii) Luna's Biebrich red for identi®cation of eosinophils; or
(iv) immunocytochemical techniques (e.g., Ki67), and were then
examined by light microscopy. Immunohistochemical staining for Ki67
Figure 1. IL-4 production by EC of IL-4 tg mice. An IL-4-speci®c
ELISA was used to quantify the amount of IL-4 in supernatants of
cultured EC from control and tg mice at the indicated time points. Data
are expressed in pg per ml as mean concentration 6 SD of duplicates.
Data represent one experiment of three.
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antigens was performed using the 3-Amino-9-Ethylcarbazole staining kit
(Dako, Vienna, Austria) according to the manufacturer's
recommendations. Ear and back skin sections were analyzed for the
presence of mast cells using Olympus BX60 (Olympus, Austria, Vienna)
and analySIS, an imaging and analysis system (Soft Imaging Systems,
Munich, Germany), which provided direct morphometric measurements
from digitized images obtained by a video camera. The entire section
areas were analyzed and the total number of mast cells per mm2 of
dermis was calculated.
Epidermal sheets from ear and back skin were prepared using the
ammonium-thiocyanate separation technique and either incubated with
the FITC-labeled anti-MHC class II MoAb M5/114 for 60 min at 37°C
or stained for ADPase activity (Elbe et al, 1989). Sheets were mounted
on glass slides in PBS/glycerol (Difco, Detroit, MI), cover slipped, and
viewed under a ¯uorescence microscope (Leitz Diaplan, Wetzlar,
Germany). Observed staining patterns were documented with a Leitz
Orthomate E system (Wetzlar) using 29 DIN arti®cial light color ®lm
(Scotch Chrome, 640-T, 3M, Milan, Italy). Labeled cells in the
epidermal sheets were enumerated at 4003 magni®cation using a
rectangular grid. Eighty to a hundred ®elds were randomly chosen and
the density of positive cells was determined and expressed as the number
of cells (6SD) per mm2 of skin surface. Experimental groups consisted of
four mice each.
Transmission electron microscopy of single EC suspensions was
performed as described (Berger et al, 1992).
Ear skin explants Ears from tg mice and controls were dissected,
rinsed with 70% ethanol, air-dried, and split with forceps into dorsal
(i.e., cartilage-free) and ventral halves. In some experiments, skin was
separated into dermis and epidermis by means of dispase before the onset
Figure 2. Acanthosis, hyperkeratosis, dermal
collagen deposition, and mast cell
accumulation in the skin of IL-4 tg mice.
Trichrome-stained ear skin sections from control
(A) and tg (B) mice revealed excessive collagen
®bers (dark blue stain) in the tg dermis. Giemsa
staining demonstrates numerous mast cells (arrows)
in the tg skin (D) in comparison with controls
(C). Scale bars: (B) 25 mm; (D) 30 mm.









9 11 25.3 6 2.4 29.2 6 4.7* 15
9 8 25.8 6 1.5 30.4 6 2.3*** 18
9 15 25.4 6 1.3 28.1 6 3.8** 11
10 15 24.3 6 1.2 29.7 6 3*** 22
10 15 26 6 1.5 29.1 6 2*** 12
10 7 26.1 6 1.7 32.4 6 2.6*** 24
a*p < 0.05; **p < 0.01; ***p < 0.001.




Mast cells per mm2 6 SD
Control IL-4 tg
17 2 ear 0.081 6 0.03 0.174 6 0.003
17 3 back skin 0.049 6 0.01 0.163 6 0.06
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of culture (Kitano and Okada, 1983; Lenz et al, 1993). Dorsal ear halves
were ¯oated dermal side down on 2 ml of culture medium in 24 well
tissue culture plates (Costar) for 3±7 d, one ear half per well (Larsen et al,
1990; Ortner et al, 1996). Depending on the duration of the culture
period, they were fed every 3 d by carefully aspirating 500 ml of spent
medium and adding back the same volume of fresh medium. Non-
adherent migratory cells were recovered from the bottom of tissue
culture wells after 3, 5, and 7 d by gentle rinsing and total cell numbers
and viability were determined by counting in a hematocytometer in the
presence of trypan blue to assess cell viability. Five 3 103 viable cells
were placed on each reaction ®eld of an adhesion slide (Bio-Rad,
Richmond, CA) and incubated in a humidi®ed chamber for 30 min at
room temperature to allow their sedimentation. Anchoring of viable cells
to the positively charged reaction ®eld was monitored under an inverted
microscope and nonattached cells were rinsed off with PBS. Attached
cells were ®xed with acetone for 10 min at room temperature and
consecutively reacted with biotinylated anti-MHC class II-Streptavidin
Texas Red/FITC-CD45 MoAb or isotype-matched control MoAb,
washed, and embedded in Glycergel (Dakopatts). Data represent the
mean 6 SD of DC per well over four wells.
Flow cytometry For two-color analyzes, cells (3 3 105 per sample)
were resuspended in cold PBS/1%FCS/0.1%NaN3 and serially incubated
with FITC-conjugated MoAb directed against selected mouse antigens
and biotinylated anti-CD45 MoAb followed by SAv-PE. For the
detection of E-cadherin molecules, EC were prepared as described (Tang
et al, 1993). Speci®city of staining was con®rmed using isotype-matched
control MoAb. Fluorescence was measured using a FACScan ¯ow
cytometer, and data were analyzed with Cell Quest software (both from
Becton Dickinson). Dead cells were excluded by 7-aminoactinomycin D
(Sigma) uptake.
Mixed lymphocyte reactions (MLR) T cells were prepared from
mesenteric lymph nodes of BALB/c mice using Ab- and C-mediated
lysis as described (Elbe et al, 1994). Brie¯y, cell suspensions were passed
through nylon wool columns, and nonadherent cells were treated with a
cocktail of the following MoAb: 3C7, 7D4, J11d.2, M5/114, IM7,
Figure 3. Loss of dermal fat tissue in IL-4 tg
mice. Giemsa-stained back skin sections from tg
mice contain less and smaller sized adipocytes (B)
than controls (A). In some tg mice the dermal fat
tissue disappeared completely (C). Scale bar:
200 mm.
Figure 4. Hyperproliferation of IL-4 tg
keratinocytes. Anti-Ki-67 immunostaining of ear
sections showed few proliferating basal cells in
controls (A) and a marked increase of proliferating
keratinocytes in IL-4 tg mice (B). (C) EC were
seeded (1 3 106 cells per well) in 24 well plates.
The number of viable adherent and nonadherent
keratinocytes, determined by trypan blue
exclusion, was counted with a hematocytometer
at the indicated time points. Results represent the
mean of keratinocytes per well over three wells.
Keratinocytes from tg mice proliferated more
vigorously than controls. SD, omitted for
simplicity, were between 15% and 30% of the
mean. p < 0.05 vs. control (10 d after culture), all
other differences are not signi®cant. Scale bar:
20 mm.
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RA3±3A1 for 30 min at 4°C. Subsequently, cells were incubated with
Low-tox-M rabbit C¢ (Cedarlane) for 45 min at 37°C; 97%±99% of
these cells were CD3+ as determined by ¯ow cytometry. To purify
CD4+ or CD8+ T cells, MoAb 3.168.81 or GK1.5 plus 2B6.2D8 were
added to the Ab cocktail. T cells were > 97% CD44low, CD45RBhigh,
CD62Lhigh as determined by ¯ow cytometry (data not shown). Control
and IL-4 tg EC were irradiated (X-ray, 15 Gray; 1.5 Gray per min,
Philips RT 305, Philips, Vienna, Austria) and cultured in 96 well round-
bottom microtiter plates (5 3 104 per well). After 3 d, puri®ed lymph
node T cells (2 3 105 per well) were added to the cultures. In other
experiments, cultured, FACS-sorted Langerhans cells were incubated
with either allogeneic CD4+ (>98%) or CD8+ (>99%) lymph node T
cells, or alone in 96 well round bottom culture plates (Costar) at 37°C.
At the indicated time points, 37 KBq (3H)-TdR was added to each well
for 10±12 h. Thereafter, cells were harvested and (3H)-TdR
incorporation was measured in a liquid scintillation counter (Packard
Instruments, Meriden, CT). Data are expressed as mean cpm 6 SD of
triplicate unless indicated otherwise.
Antigen-processing assays The processing activity of control and tg
Langerhans cells (H-2b/k) was measured using MHC class II-restricted T
cell hybridomas (C10.9, HEL-speci®c, I-Ak-restricted, E8, OVA-speci®c,
I-Ek-restricted). The activation of hybridoma cells was determined by
measuring IL-2 production by ELISA (Endogen). Brie¯y, freshly
prepared control and tg EC were treated with anti-Thy-1.2 MoAb for
30 min at 4°C, followed by Low-Tox-M-rabbit C¢ for 40 min at 37°C
to deplete some keratinocytes and epidermal T cells. After removal of
dead cells by density gradient centrifugation, resulting cells (1.5 3 106
cells per ml) were cultured either with or without HEL (1 mg per ml)
and OVA (2 mg per ml) for 20 h in 24 well plates. Thereafter,
nonadherent cells were adjusted to equal numbers of Langerhans cells as
determined by ¯ow cytometry. Antigen-pulsed and, for control purposes,
unpulsed control and tg Langerhans cells (5 3 103 per well) were
cultured either with hybridoma cells (105 per well) or alone in 96 well
¯at-bottom microtiter plates. Supernatants were harvested after 24 h and
stored at ±20°C until use.
Statistical analysis Two-tailed t test was used to evaluate the
signi®cance of experimental versus control groups.
RESULTS
IL-4 tg EC produce IL-4 To test whether functional protein is
produced in tg epidermis, we examined the supernatants of EC
cultures for the presence of IL-4 by ELISA. As shown in Fig 1,
supernatants from cultures derived from tg mice contained at all
time points elevated amounts of IL-4 relative to cultures derived
from control mice.
IL-4 alters the skin architecture Tg mouse skin appeared dry
with signs of scaling but exhibited no macroscopic signs of skin
disease. Light microscopic examination of ear sections (Figs 2A, B)
and ear measurements (Table I) revealed a signi®cantly thickened
skin in tg mice compared with controls. This was partly due to
acanthosis and hyperkeratosis and partly to deposition of
collagenous material in the super®cial and deep dermis as
demonstrated by trichrome staining (Figs 2A, B). Giemsa-stained
sections revealed an increase in mast cell numbers in the ear and
back skin dermis of tg mice by a factor of approximately two
(Figs 2C, D, Table II). In contrast to control mice, considerable
numbers of mast cells in the tg skin were located between fat cells
and in the muscle layer. The observation that the tg dermis had less
and smaller sized adipocytes than control dermis was striking
(Figs 3A, B). In some tg mice the dermal fat tissue disappeared
completely (Fig 3C). (Immuno)histochemistry of the tg dermis
showed no evidence of acute in¯ammation (no eosinophil, T cell,
macrophage and neutrophil in®ltration) (data not shown). Two
approaches were chosen to study the hyperplastic epidermal
morphogenesis. First, proliferating keratinocytes were identi®ed
by immunohistochemistry. Although Ki-67+ nuclei were observed
in the basal skin layer of both control and tg mice (Figs 4A, B), the
proportion of Ki-67+ cells was greater in tg mice, indicating
accelerated proliferation of epidermal keratinocytes. Scattered Ki-
67+ cells were also identi®ed in the suprabasal layers of the tg
epidermis (data not shown). In a second series of experiments, we
compared the yields of viable cells in keratinocyte cultures from
control and tg mice at selected time points. Over the entire
observation period of 10 d, we found a 2±3-fold increase of
keratinocyte cell numbers in cultures isolated from tg mice
(Fig 4C). Thus, we conclude that IL-4 causes keratinocyte
hyperproliferation, induces mast cell accumulation and dermal
collagen deposition, and leads to a loss of fat tissue in the dermis.
Impaired emigration of IL-4 tg Langerhans cells from ear
skin explants IL-4 has been described as a factor enhancing the
yield of bone marrow-derived DC in vitro (Lutz et al, 2000). We
investigated if and how IL-4 in¯uences the numbers of epidermal
Langerhans cells in our tg mice. Epidermal sheets from the ears of
control and tg mice were prepared and the distribution and
numbers of Langerhans cells were compared. Immunophenotypic
and quantitative analyzes revealed that the epidermis from tg mice
contained 2±3-fold higher numbers of dendritic MHC class II+
cells than controls (Fig 5A±C). Notably the tg epidermis contained
clusters with cells that stained much more brightly with an anti-
MHC class II MoAb than Langerhans cells from control animals
(Fig 5B, inset). By using ADPase, a well-recognized marker for
Langerhans cells, we found that, similar to the measurement of
MHC class II+ cells, the numbers of dendritic, ADPase+ cells in the
epidermis of tg mice were increased 2±3 times as compared with
Figure 5. Accumulation of Langerhans cells in the IL-4 tg
epidermis. Ear epidermal sheets from control (A, D) and IL-4 tg mice
(B, E) were either exposed to the FITC-labeled anti-MHC class II
MoAb M5/114 (A, B) or stained for membrane ADPase activity (D, E).
The epidermis from tg mice (black columns) contained 2±3-fold higher
numbers of dendritic MHC class II/ADPase+ cells than controls (hatched
columns). It is notable that the tg epidermis contained several clusters
with Langerhans cells that stained much more brightly with the anti-
MHC class II MoAb (inset), and that tg Langerhans cells show stronger
ADPase activity than control Langerhans cells (D, E). p < 0.001 vs.
control (C), p < 0.01 vs. control (F). Scale bars: (B) 50 mm; (inset) 25 mm;
(E) 20 mm.
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controls (Fig 5D±F), implying that most, if not all, MHC class II+
cells in the tg mouse epidermis are indeed Langerhans cells. Similar
to our ®nding in the ear epidermis, the numbers of MHC class II+/
ADPase+ cells with dendritic morphology were increased in the
abdominal epidermis from tg mice (data not shown). Several
possible hypotheses exist to explain the accumulation of Langerhans
cells in these mice, i.e., (i) Langerhans cell proliferation in situ, (ii)
increased in¯ux of Langerhans cell progenitors from the blood into
the skin, (iii) a decreased ef¯ux of Langerhans cells from the
epidermis, and (iv) reduced apoptosis of Langerhans cells. By
electron microscopy, we found that tg Langerhans cells, similar to
controls, displayed an indented nucleus and contained typical
Birbeck granula. Regular cell organelles such as Golgi, endoplasmic
reticulum, and mitochondria were well developed (data not
shown). The screening of numerous sections revealed no mitotic
Langerhans cells in control and tg skin, suggesting that the
enhanced Langerhans cell density in the tg mouse epidermis is not
due to in situ proliferation. To test whether IL-4 overexpression
causes an abnormal in¯ux of Langerhans cell progenitors from the
blood to the skin, epidermal sheets from newborn tg and control
mice were assessed for the presence of Langerhans cells.
Surprisingly, we found less ADPase+ cells in the newborn tg
epidermis compared with controls. Fourteen days postpartum the
numbers of ADPase+ cells in the tg epidermis and in the controls
were similar and later increased in tg mice (data not shown). These
data imply that IL-4, either directly or indirectly, partially inhibits
the entry of Langerhans cell precursors into the epidermis. The ear
skin explant model was used to test the hypothesis that tg mice have
a de®ciency in the Langerhans cell mobilization. This model allows
for the examination of Langerhans cell migration from the
epidermis to the dermal lymphatics and may re¯ect, in part, their
in vivo migratory capacity (Larsen et al, 1990). We found that over
3 d of culture, the relative decrease of Langerhans cells in the
epidermis was greater in control than in tg mice (Figs 6A, B, G).
In control mice, migrating DC accumulated in a characteristic
string-like pattern (i.e., cords) in dermal lymphatic vessels
(Figs 6C, E), whereas cords were reduced in tg mice, and if
present, contained only few MHC class II+ cells (Figs 6D, F). At
later time points (days 5±7) cords were also formed, though
considerably less abundant than in controls (data not shown).
Emigration was measured by counting the numbers of Langerhans
cells/DC present in the culture medium. After 3 d, the numbers of
emigrated MHC class II+, CD45+ Langerhans cells/DC from the
skin of control mice was 4±5-fold higher than from tg skin
(Fig 6H). Even after 5 d of culture, Langerhans cells/DC numbers
present in the wells with tg skin explants were lower when
compared with numbers obtained from control skin explants (data
not shown). To test whether tg Langerhans cells per se are able to
leave the epidermis, epidermal sheets were cultured and the
emigration capacity of Langerhans cells was tested. After 3 d, the
number of emigrated MHC class II+, CD45+ Langerhans cells from
the epidermis of tg mice was 2±3-fold higher than from control
epidermis (numbers of cells per ear half: tg: 2.6 3 104 6 0.4;
control: 0.7 3 104 6 0.1). In accordance with this was the
observation that the cultured epidermis from both tg and control
mice was almost negative for MHC class II+ cells. In conclusion,
these data suggest that tg Langerhans cells, similar to control
Langerhans cells, are able to leave the epidermis as such but, in
contrast to control Langerhans cells, they are less capable of passing
the epidermal basement membrane in intact skin and entering the
lymphatic vessels. Alternatively, an IL-4-induced product (e.g., IL-
4 activated mast cells) could possibly inhibit Langerhans cell
migration from the epidermis in IL-4 tg mice. Cytokines produced
by EC in situ are thought to play a major role in Langerhans cell
survival and migration. To investigate whether differences in the
cytokine milieu between control and tg epidermis could be
responsible for the failure of tg Langerhans cells to migrate to the
dermis, we compared the cytokine production in EC cultures
derived from control and tg mice. Surprisingly, we found that the
levels of cytokines that are known to promote Langerhans cell
emigration, survival, and maturation (e.g., TNF-a, GM-CSF, IL-
1) (Koch et al, 1990; Wang et al, 1997; Stoitzner et al, 1999) were
higher in the supernatants of tg EC than in those from control mice
(Fig 7). Taken together our data suggest that the reduced
emigration of epidermal Langerhans cells in skin explants may be
a result of a cytokine imbalance in the skin of tg mice. Whether
Figure 6. Impaired migration of IL-4 tg Langerhans cells out of
skin explants. Dorsal ear skin from control (A, C, E) and IL-4 tg (B,
D, F) mice was ¯oated on medium and cultured in 24 well plates. After
3 d, epidermal (A, B) and dermal (C±F) sheets were prepared and stained
with the FITC-labeled anti-MHC class II MoAb M5/114. Considerably
more Langerhans cells could be detected in tg epidermis compared with
controls (A, B, G, tg = black columns, control = hatched columns).
MHC class II+ cells in epidermal sheets were counted and expressed as
the mean 6 SD. In the dermis, migrating DC formed cords within the
dermal lymphatics of control mice (C, E). In contrast, these cords were
hardly detectable in tg mice (D, F). After 3 d, nonadherent cells were
harvested from the bottom of wells and the total cell number was
determined by counting with a hematocytometer. The proportion of
DC was calculated by examining anti-FITC-CD45, biotinylated MHC
class II-TR-SA-stained adhesion slides. Results represent the mean 6 SD
of DC per well over four wells (H, tg = black column, control =
hatched column). The number of emigrated DC from the skin of
control mice was 4±5-fold higher than from tg skin. p < 0.001 vs.
controls (G, H). Scale bars: (B, F) 50 mm; (D) 100 mm.
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cytokines other than those investigated are also changed cannot be
de®nitively excluded at this point. We are currently performing
studies to determine which other cytokines and chemokines are
induced in IL-4 EC in situ.
The overexpression of IL-4 affects the Langerhans cell
phenotype in situ To test whether IL-4 and the changed
epidermal cytokine milieu affects the expression of cell surface
molecules on Langerhans cells, we analyzed the phenotype of
freshly isolated tg and control Langerhans cells. Flow cytometry
corroborated the immunohistochemistry results that 2±3-fold more
CD45+, MHC class II+ Langerhans cells are present in the IL-4 tg
epidermis as compared with controls (Fig 8A). Furthermore, in
contrast to control Langerhans cells, we found a slight upregulation
of MHC class II, e-cadherin, CD54, and CD86 on a subpopulation
of tg Langerhans cells (Fig 8A, and data not shown). Molecules like
FcgR, integrins (CD11b, CD11c, CD29), CD24, CD44, and F4/
80 were similarly expressed on the surface of control and tg
Langerhans cells (Fig 8A, and data not shown). Like control
Langerhans cells, freshly prepared tg Langerhans cells failed to
express CD25, CD23, and CD80 (data not shown). In summary,
these data demonstrate that IL-4 only slightly changes the
phenotypic pro®le of Langerhans cells in situ.
IL-4 tg Langerhans cells are equally potent stimulators of
naõÈve allogeneic T cells but superior to control Langerhans
cells in their ability to process native protein antigens To
determine whether tg Langerhans cells are able to mature in
culture, EC were isolated, incubated for 3 d, enriched for
Langerhans cells by density gradient centrifugation and analyzed
by ¯ow cytometry. Both control and tg Langerhans cells exhibited
a similar increase in the cell surface expression of CD29, CD44,
CD40, CD54, CD80, and CD86 as well as a similar decrease in the
expression of FcgR, e-cadherin, CD24, and F4/80 molecules. Tg
Langerhans cells, however, expressed considerably less DEC-205
and more CD49d than control Langerhans cells. Most Tg
Langerhans cells failed to express CD25 (Fig 8B, and data not
shown). To clarify whether such phenotypic differences in¯uence
the functional capacity of Langerhans cells, control Langerhans cells
were compared with tg Langerhans cells in different antigen
presentation assays. We used the allogeneic MLR to investigate the
capacity of cultured EC/Langerhans cells to induce primary T cell
responses. When EC were used as stimulators in these assays, the
proliferative T cell response induced by tg EC was approximately
2-fold higher than with control EC [tg: 70.812 cpm; control:
39.680 cpm (n = 3)]. When equal numbers of Langerhans cells
were compared in the allogeneic MLR, however, both the
magnitude and the kinetics of the proliferative response induced
by tg Langerhans cells compared with those induced by control
Langerhans cells, with a peak occurring on days 4 and 5 for CD8+
and CD4+ T cells, respectively (Fig 9A). We next determined
whether Langerhans cells that remain in the epidermis of skin
explants over 5 d of culture are viable and functional. Therefore, at
the end of the culture period, the epidermis was separated from the
dermis by trypsin digestion and the Langerhans cell numbers were
determined. When equal numbers of such control and tg
Langerhans cells were used as stimulators in MLR assays, the
proliferative T cell response induced by tg Langerhans cells was
comparable with that evoked by control Langerhans cells. Not only
the magnitude but also the kinetics of this response were
comparable, with a peak of the proliferation observed on days 3±
4 (data not shown). These ®ndings show that tg Langerhans cells,
although surrounded by a different cytokine milieu and control
Langerhans cells, are comparable stimulators in the MLR. To
further analyze whether the altered Langerhans cell phenotype in tg
mice in¯uences their ability to process and present native protein
antigen, we performed antigen-processing assays. We found that
the presentation of HEL (Fig 9B) and OVA (Fig 9C) protein to
the respective MHC-class II-restricted T cell hybridomas was
substantially higher in tg than in control Langerhans cells. In
conclusion, these data show that tg Langerhans cells, similar to
Figure 7. Cytokine pattern of IL-4 tg EC culture supernatants.
EC isolated from control (hatched columns) and tg (black columns) mice
were cultured for the indicated time points. Supernatants were screened
for the presence of TNF-a, GM-CSF, and IL-1a by ELISA. Data are
expressed in pg per ml as mean concentration 6 SD of triplicates. p
< 0.01 (24 h), p < 0.05 (48 h) (A); p < 0.05 (24 h), p < 0.01 (48 h) (B);
differences in (C) are not statistically signi®cant.
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control Langerhans cells, mature into potent stimulators of naõÈve,
allogeneic T cells and that freshly isolated tg Langerhans cells are
two times more ef®cient than control Langerhans cells in taking up,
processing, and presenting native protein antigens.
DISCUSSION
Because IL-4 is produced in AD skin (Kapsenberg et al, 1992;
Hamid et al, 1994), the possibility has been raised that this cytokine
plays an important role in the pathogenesis of this disease.
Therefore, we have examined IL-4 tg mice to study the
consequences of IL-4 overexpression for the skin. Tg mice had
no signs of spontaneous skin disease, but displayed histopathologic
changes involving both the epidermis and the dermis, including
epidermal hyperplasia, hyperkeratosis, an increase of Langerhans
cells, an upregulation of speci®c surface markers on a subpopulation
of Langerhans cells, proliferation of ®broblasts, an accumulation of
collagen and mast cells in the dermis, and a reduction of skin
adipocytes.
Among all pathologic changes induced by IL-4 transgene
expression, its in¯uence on adipocytes is of particular interest.
Results demonstrate that overexpression of IL-4 leads to a dramatic
reduction of fat cells (both in number and in cell size). To our
knowledge this is the ®rst report to describe such effects of IL-4
in vivo. In hematopoietic cells, IL-4 is the prototypical activator of
Stat-6 (Nelms et al, 1999). It has only been shown recently that
IL-4 signals through Stat-6 in preadipocytes and induces tyrosine
phosphorylation of other proteins in mature adipocytes (Deng et al,
2000); however, the molecular mechanism leading to fat reduction
in IL-4 tg mice is currently unclear. In AD patients such a
phenomenon has not been described yet, but it is conceivable that
the extra infraorbital eylid fold (Leung et al, 1993) may be a
consequence of reduced fat cells.
A prominent ®nding in chronic AD lesions is ®brosis of the
upper dermis (Leung, 1995). Similarly, we found in IL-4 tg skin a
subepidermal or upper dermal ®brosis characterized by ®broblast
accumulation stretching along regions beneath the epidermis.
Histochemical staining revealed a meshwork of collagen in these
areas. Other signs of ®brosis, e.g., hydroxyproline levels, have not
yet been determined in these mice. Furthermore, we cannot
exclude the possibility that IL-4 induced the skin to secrete another
pro-®brotic factor, such a TGF-b (Rose and Leskovsek, 1998),
which in turn might be responsible for the dermal ®brosis in these
mice; however, we consider this possibility rather unlikely because
we found no in®ltrating T lymphocytes in the tg skin and evidence
that IL-4 indeed plays an important role in the etiology of skin
®brosis comes from several observations. The development of skin
®brosis in tight-skin mice, an experimental mouse model of
heritable systemic ®brosis that bears some similarities to human
scleroderma, was abrogated by (i) the administration of neutralizing
anti-IL-4 antibodies (Ong et al, 1998) and (ii) IL-4±/±, Stat6±/±, IL-
4Ra±/± mutation (Ong et al, 1999; McGaha et al, 2001).
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Figure 8. Phenotypic characteristics of freshly isolated and cultured IL-4 tg Langerhans cells. Freshly prepared EC were stained and analyzed
by ¯ow cytometry (A). Three day-cultured, nonadherent EC were enriched for Langerhans cells by density gradient, washed, stained, and analyzed (B).
In all experiments, stained cells were gated for viable cells and 10 000 events per sample were acquired. Dot plots represent results of 12 (A) or three
(B) independent experiments.
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Furthermore, it has been shown that IL-4 stimulates collagen gene
expression in ®broblasts (Gillery et al, 1992). In our mice ®broblasts
themselves produce IL-4 and most likely induce collagen accumu-
lation in an autocrine fashion.
Another remarkable feature was that the overexpression of IL-4
in the skin leads to changes in keratinocyte proliferation. This is
supported by the observation that in the epidermis of IL-4 tg mice
the mitotic index was increased by approximately 2±4 times when
compared with control mice. The proliferating cells were located in
the basal layer and, to a lesser extent, at a suprabasal layer.
Keratinocytes are known to be activated by IL-4, because it has
been shown to stimulate human keratinocyte proliferation in vitro
(Junghans et al, 1996; Yang et al, 1996). Therefore, we conclude
that IL-4 released by EC in our mice is an autocrine stimulator of
keratinocytes that evokes their proliferation, resulting in epidermal
hyperplasia. In addition, our ®ndings con®rm that the expressed IL-
4 is biologically active in vivo. These results were different to those
of a most recent study of tg mice were IL-4 was speci®cally
expressed in the epidermis (Chan et al, 2001). Whereas normal
appearing skin in these mice revealed essentially no pathology, only
the chronic in¯ammatory lesions demonstrated hyperkeratosis and
hyperproliferation (Chan et al, 2001). The reasons for these
differences are not known but it is conceivable that due to the
ubiquitous expression of IL-4 in our model, its effects are more
severe.
In terms of the composition of the cellular in®ltrate in the IL-4 tg
skin, mast cells and Langerhans cells were the most abundant cell
types, whereas T lymphocytes and eosinophils were sparse or absent
and macrophage numbers were not increased. These data are in
contrast to ®ndings in IL-4 tg mice expressing IL-4 in the epidermis
(Chan et al, 2001). Similar to our study they do not ®nd cellular
in®ltration with T cells and eosinophils in normal appearing skin;
however, they found these cells in early and chronic in¯ammatory
lesions. The reasons for these differences are not clear. It is
conceivable that in our model IL-4-induced chemokines (e.g.,
eotaxin) are produced in many tissues, not only skin, thus
abolishing the gradient required for selective recruitment of
eosinophils and T cells. Furthermore, our tg mice, in contrast to
those of Chan et al (2001), have reduced peripheral T cell densities
and in addition to that many of the residual T cells exhibit the
CD44highMel-14low phenotype (Erb et al, 1994) that might alter
their skin-homing capabilities. Another explanation may be that
IL-4 in our mouse model failed to induce VCAM-1 expression on
venular endothelial cells and, thus, T lymphocytes and eosinophils
were not able to migrate to the skin. Indeed, preliminary
immunohistochemical stainings of IL-4 tg skin showed no
VCAM-1 expression (F. Koszik, unpublished observation).
Accumulations of mast cells have been associated with several
cutaneous diseases, including atopic diseases and psoriasis, while
their role is still obscure. Th cells cannot differentiate into IL-4-
producing Th2 subtype without an initial pulse of exogenous IL-4.
As mast cells have been shown to contain and secrete IL-4
(Horsmanheimo et al, 1994), they could provide the initial amount
of IL-4 needed by the Th2 cells in AD. In accordance with this,
evidence exists that IL-4 sustains and promotes the growth and
development of murine mast cells in vitro (Hamaguchi et al, 1987).
Therefore, the ®nding that IL-4±/± mice have normal numbers of
dermal mast cells was surprising (Hart et al, 2000); however, these
mast cells are dysfunctional with respect to expression of c-kit, the
receptor for stem cell factor, and degranulation upon UVB-
irradiation (Hart et al, 2000), implying that in the absence of IL-4
mast cells cannot differentiate. Our observation that mast cells are
increased in IL-4 tg mice suggests that IL-4 is also a growth-
promoting cytokine for these cells in vivo and supports a previous
observation in IL-4 tg mice expressing IL-4 in the epidermis (Chan
et al, 2001).
One of the most striking features in the skin of IL-4 tg mice was
an increase in the numbers of Langerhans cells in the epidermis.
Our data suggest that this accumulation of Langerhans cells was not
due to their in situ proliferation, but rather due to their impaired
ef¯ux from the epidermis to the dermis. It remains to be
investigated whether this is a direct or indirect effect of IL-4.
Keratinocytes express IL-4R (Junghans et al, 1996; Wery-Zennaro
et al, 1999) and, thus, can respond to IL-4. Therefore, it is
conceivable that IL-4-activated tg keratinocytes release mediators
that may affect the migration of tg Langerhans cells. Langerhans cell
migration is initiated and regulated by in¯ammatory mediators such
as TNF-a (Cumberbatch et al, 1994; Kondo et al, 1995; Wang et al,
1997); however, recent results from skin organ cultures revealed
that high concentrations (5000 U per ml) of TNF-a can partially
inhibit Langerhans cell migration (Stoitzner et al, 1999). In analogy
to these ®ndings higher amounts of TNF-a produced by tg EC
may be suf®cient to hinder tg Langerhans cell emigration out of the
skin. Alternatively, IL-4 itself may be responsible for the decreased
ef¯ux of Langerhans cells, as it has been shown with human
Langerhans cells that IL-4 can inhibit their migratory activity by
downregulating the expression of TNF-RII (Takayama et al, 1999).
Whether a similar mechanism and/or other receptors play a role in
Figure 9. Antigen-presenting capacity of IL-4 tg Langerhans cells in vitro. EC from control and tg mice were cultured for 3 d, sorted by
FACS, and cocultured (1 3 103 per well) with naõÈve, allogeneic CD4+, or CD8+ T cells (1 3 105 per well) in 96 well round-bottom microtiter plates
(A). Proliferative responses were determined on days 3±6 of culture. Error bars represent SD of triplicate cultures. Data shown are representative of
three experiments. Langerhans cells, CD4+, and CD8+ T cells did not proliferate when cultured with medium alone (< 1000 cpm). T cells did not
respond to Con A when cultured in the absence of Langerhans cells. Freshly isolated control (hatched columns) and IL-4 tg (black columns) EC were
cultured in the presence of HEL (B) and OVA (C) for 20 h and enriched for Langerhans cells. HEL and OVA-pulsed control and tg Langerhans cells
(5 3 103 per well) were cocultured with the respective hybridoma cells (105 per well) in 96 well ¯at-bottom microtiter plates for 24 h. Supernatants
were harvested and IL-2 concentrations were determined by ELISA. C10 and E8 T cell hybridomas failed to produce IL-2 when cultured alone or
with unpulsed Langerhans cells (data not shown). p < 0.01 (B); p < 0.05 (C).
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our mouse model remains to be investigated. Evidence that IL-4
prevents Langerhans cell emigration in vivo comes from a study
using contact hypersensitivity (BluÈmel et al, 1999). When BluÈmel et
al employed the same type of mice as used in this study, they found
enhanced epidermal IL-6 gene expression and reduced numbers of
MHC class II+/CD80+ cells in the ear-draining lymph nodes of tg
mice after sensitization with oxazolone compared with controls,
and concluded that this might be due to a decreased migration of
epidermal-derived antigen-presenting cells resulting in a reduced
antigen presentation in the draining lymph nodes. Furthermore,
they found a signi®cantly increased TNF-a and MIP-2 gene
expression in the epidermis of hapten-treated IL-4 tg but not in
sensitized control mice. On the basis of these ®ndings they assumed
that the reduced migration of epidermal Langerhans cells towards
the skin-draining lymph nodes is a result of a cytokine imbalance in
the skin of IL-4 tg mice, which is in line with our data.
It is possible that not only the reduced capacity of tg Langerhans
cells to emigrate out of the skin, but also their enhanced longevity
may be responsible for the increased numbers of these cells in the
epidermis. It has previously been shown that keratinocyte-derived
cytokines (e.g., GM-CSF, IL-1, TNF-a) promote survival and
maturation of Langerhans cells (Witmer-Pack et al, 1987; Heu¯er et
al, 1988; Koch et al, 1990). We observed that the spontaneous
release of all these cytokines was increased in supernatants of
unstimulated tg EC compared with supernatants from control EC
and could, thus, prolong survival of Langerhans cells. Indeed, our
preliminary data indicate that GM-CSF extends survival of FACS-
sorted tg Langerhans cells in vitro compared with control
Langerhans cells (A. Elbe-BuÈrger, unpublished observation). In
this regard also keratinocytes from AD patients have an enhanced
GM-CSF production and increased numbers of Langerhans cells
(Pastore et al, 1997), a picture that is similar to our mice.
Functionally, we found that the tg Langerhans cells were equally
potent stimulators of the allogeneic MLR as control Langerhans
cells, whereas tg Langerhans cells were more ef®cient in their
capacity to present a soluble protein antigen than control
Langerhans cells, which might be a consequence of augmented
antigen uptake. Indeed, it has been shown only recently that GM-
CSF either alone or in combination with IL-4 augments the rate of
pinocytosis by DC (Lutz et al, 1996), a mechanism that might also
be operative in tg Langerhans cells.
Our ®ndings identify IL-4 as a potent multifunctional cytokine at
the skin site that is capable of evolving numerous in¯ammatory
processes ranging from epidermal hyperplasia to ®brotic responses
and suggest that IL-4 is not only a key cytokine in the development
of AD but seems to play an important role for the perpetuation of
pathologic changes in chronic skin conditions, including chronic
AD. Thus, IL-4 tg mice are a unique model to further study certain
aspects of AD pathogenesis, and suggest that IL-4 antagonists may
ameliorate some key features of AD.
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